The New Mounjaro Rules UK Patients Are Asking About

The biggest misconception: 'new rules' means you can no longer get Mounjaro privately

A lot of the anxiety circulating online right now traces back to one misreading: that the new rules introduced in 2025 restrict who can access tirzepatide full stop. That is not accurate. The NICE TA1026 guidance (published in December 2024 and updated in September 2025) sets out phased criteria for NHS prescribing specifically. It does not alter the licensed eligibility for private treatment. If you've heard that Mounjaro is now unavailable unless you have four serious conditions and a BMI above 40, that description applies to the first wave of NHS commissioning, not to a legitimate private prescription.

For private patients, the clinical criteria for tirzepatide remain as the medicine's licence sets them: adults aged 18 or over with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A prescriber still assesses the whole picture, a BMI that meets the threshold does not automatically mean the medicine is right for you.

The detail of what NICE TA1026 actually says is worth reading directly. NICE's appraisal of tirzepatide (TA1026) is publicly available and covers both the phased NHS rollout and the clinical evidence base. It's a reasonable first stop if you want the unfiltered version.

What the NHS eligibility phases actually say

The phased rollout is stricter than most news coverage suggested at launch. The first cohort, active from June 2025, requires a BMI of 40 or above plus four or more of five qualifying conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. A second cohort opened in June 2026, covering adults with a BMI of 35 to 39.9 alongside four or more of those same conditions. A third cohort, targeting BMI of 40 or above with three conditions, is expected around March 2027. Ethnic-background BMI thresholds are 2.5 kg/m² lower throughout.

Even meeting those criteria does not guarantee rapid access. From 1 April 2026, GP practices can prescribe under the updated QOF contract, but participation is voluntary, availability varies by practice and region. Every NHS patient must also engage with wraparound diet and activity support as a condition of treatment. The NHS England guidance on weight-management injections sets this out clearly and is worth reviewing if you're exploring the NHS route.

If you don't meet the current NHS thresholds or simply cannot wait, a private prescription through a GPhC-registered pharmacy is the legal alternative. You can find out more about what has changed with Mounjaro access and whether the private route suits your situation.

The price change: what happened on 1 September 2025

Separate from the NHS commissioning changes, Eli Lilly raised Mounjaro's UK list price on 1 September 2025. The move was widely reported at the time, and our guide to the new Mounjaro rule changes explains what those updates mean in practice for patients considering the private route. At the highest dose, the list price rose from around £122 to around £330 per four-week pen. Private providers set their own prices on top of that list price, so the typical private market range since September 2025 runs roughly £149 to £375 per month depending on the dose and the pharmacy, though those figures vary and are worth checking directly with any provider you're considering.

If you've been comparing providers, our overview of Mounjaro costs in the UK explains what legitimate private pricing includes and what some headline figures leave out. The short version: a legally-supplied private prescription has to include an actual clinical assessment and a valid prescription. Any price that seems to skip those steps is a red flag, not a bargain.

It's understandable to feel unsettled by all of this. The rules changed, the price changed, and the reporting has been uneven. What hasn't changed is the basic requirement: a prescriber who has actually reviewed your health must issue a prescription before any pharmacy can legally supply tirzepatide.

What changes at a private regulated pharmacy

At a private pharmacy, the new Mounjaro rules in the UK don't alter the clinical process. Every consultation is reviewed by a GPhC-registered Independent Prescriber (not a screening algorithm) before a prescription is issued. Identity is verified by photo ID, and weight is confirmed on a live video call. Transfer patients are asked for evidence of their current dose before continuing. That level of clinical oversight is what the rules for Mounjaro prescribing require, and what any legitimate regulated provider should be following.

You can verify that a pharmacy is GPhC-registered before you use it at the GPhC register entry for our pharmacy (registration number 9012878). For broader context on how Mounjaro works and who it's licensed for, that page covers the mechanism, the trial evidence, and the practical steps involved in treatment. Our clinical team is available seven days a week for aftercare questions once treatment has started.

If you'd like a prescriber to assess your situation properly and discuss whether tirzepatide is right for you, speak to our prescribers, the consultation is free, and there's no obligation.